| Methods |
4‐week placebo run‐in; inclusion criteria= mean supine DBP 95‐115 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
Valsartan 10 mg: n=25(19 males,6 females); mean age=54.3(10.1) years: baseline supine SBP=157.3(13.8) mm Hg, DBP=102.6(5.8) mm Hg;
Valsartan 40 mg: n=25(17 males,8 females); mean age=52.4(9.3) years; baseline supine SBP=150.7(13.5) mm Hg, DBP=101.8(5.3) mm Hg;
Valsartan 80 mg: n=23(19 males,4 females); mean age=52.3(12.9) years; baseline supine SBP=152.7(13.4) mm Hg, DBP=100.7(5.0) mm Hg;
Valsartan 160 mg: n=24(12 males,12 females); mean age=52.2(10.2) years; baseline supine SBP=155.1(15.7) mm Hg, DBP=101.0(5.2) mm Hg;
Placebo: n=25(12 males,13 females); mean age=53.0(9.3) years; baseline supine SBP=156.4(17.6) mm Hg, DBP=101.7(4.9) mm Hg |
| Interventions |
Valsartan 10 mg once daily;
Valsartan 40 mg once daily;
Valsartan 80 mg once daily;
Valsartan 160 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Adjusted mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change and SD of change not reported, endpoint BP and SD not reported, baseline SD reported; imputed baseline SBP SD for SBP SD of change, imputed overall trial mean DBP SD of change; BP data from text, p. 277 and p. 279; Jadad score=4; funding source= Novartis |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
